Literature DB >> 9629521

Neurochemical dissection of synaptic pathology in Alzheimer's disease.

P Davidsson1, K Blennow.   

Abstract

Synaptic pathology has attained increasing attention as being central in the pathogenesis of Alzheimer's disease (AD). To address the question whether synaptic pathology in AD involves the whole synapse, or is limited to specific components thereof, we studied three different synaptic vesicle proteins (rab3a, synaptotagmin, synaptophysin) and also the presynaptic membrane protein GAP-43 and the postsynaptic protein neurogranin. The material included postmortem brain tissue (frontal cortex, hippocampus, and cerebellum) from 8 patients with early-onset AD (EAD), 11 patients with late-onset AD (LAD), 6 patients with vascular dementia (VAD), and 9 control subjects. A reduction of all synaptic proteins was found in AD, more pronounced in EAD than in LAD, in both the frontal cortex (EAD 30% to 70% vs. LAD 82% to 88% of control value) and hippocampus (EAD 22% to 82% vs. LAD 76% to 89% of control value), whereas only minor changes were found in VAD. The finding that all synaptic proteins were reduced in AD suggests a degeneration and loss of whole synaptic elements that are more pronounced in EAD than in LAD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629521     DOI: 10.1017/s1041610298005110

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  58 in total

1.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

2.  Hippocampal drebrin loss in mild cognitive impairment.

Authors:  Scott E Counts; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Elliott J Mufson
Journal:  Neurodegener Dis       Date:  2012-02-04       Impact factor: 2.977

3.  Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.

Authors:  Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin
Journal:  Neurology       Date:  2018-06-29       Impact factor: 9.910

Review 4.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 5.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

6.  Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Dan Crimmins; Elizabeth Herries; Terry Griest; Anne M Fagan; Gregory J Zipfel; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

Review 7.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

Review 8.  Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Authors:  Simone Lista; Henrik Zetterberg; Bruno Dubois; Kaj Blennow; Harald Hampel
Journal:  J Neurol       Date:  2014-05-08       Impact factor: 4.849

9.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model.

Authors:  Amee J George; Lavinia Gordon; Tim Beissbarth; Irene Koukoulas; R M Damian Holsinger; Victoria Perreau; Roberto Cappai; Seong-Seng Tan; Colin L Masters; Hamish S Scott; Qiao-Xin Li
Journal:  Neurotox Res       Date:  2009-09-16       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.